Immunocore Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Immunocore Holdings şirketinin toplam hissedar öz sermayesi $377.8M ve toplam borcu $438.7M olup, bu da borç-öz sermaye oranını 116.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $1.1B ve $706.8M dir.

Anahtar bilgiler

116.1%

Borç/özkaynak oranı

US$438.70m

Borç

Faiz karşılama oranı	n/a
Nakit	US$901.28m
Eşitlik	US$377.83m
Toplam yükümlülükler	US$706.81m
Toplam varlıklar	US$1.08b

Son finansal sağlık güncellemeleri

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Oct 24

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

May 11

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Jan 22

Recent updates

Immunocore Is Adequately Valued, But Its Prospects Are Uncertain

Dec 10

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Oct 24

Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Sep 19

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Aug 12

Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?

Jul 24

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Jun 16

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

May 11

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Apr 05

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Jan 22

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Jan 21

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Dec 18

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

May 08

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Nov 16

Immunocore: Attractive Commercial-Stage Biopharma

Oct 05

Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Aug 12

Immunocore GAAP EPS of -$0.17, revenue of $38.92M

Aug 10

Immunocore to raise $140M in private placement financing

Jul 18

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IMCR 'nin kısa vadeli varlıkları ( $1.0B ) kısa vadeli yükümlülüklerini ( $266.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: IMCR şirketinin kısa vadeli varlıkları ( $1.0B ) uzun vadeli yükümlülüklerini ( $440.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IMCR şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: IMCR 'nin borç/öz sermaye oranı son 5 yılda 197.8% seviyesinden 116.1% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan IMCR mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: IMCR kârlı değildir ancak serbest nakit akışının pozitif olması ve yılda % 36.1 oranında büyümesi nedeniyle 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 08:01
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Immunocore Holdings plc 22 Bu analistlerden 15, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jack Allen	Baird
Peter Lawson	Barclays
Olga Smolentseva	Bryan Garnier & Co

Immunocore Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Recent updates

Immunocore Announces Treatment of First Patient in the Phase 1/2 Trial of IMC-R117C Targeting PIWIL1 in Advanced Gastrointestinal Cancers

European Organisation for Research and Treatment of Cancer and Immunocore Holdings plc Announces Enrolment of First Patient Onto Phase 3 Adjuvant Trial in Oveal Melanoma

Immunocore Is Adequately Valued, But Its Prospects Are Uncertain

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates upgraded to US$1.10 loss

New major risk - Revenue and earnings growth

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Immunocore Presents Phase 1 Data of Brenetafusp, an Immtac Bispecific Targeting Prame, in Patients with Ovarian Cancer

Immunocore Holdings plc Announces Brian Di Donato Plans to Leave At the End of the Year as Chief Financial Officer

Consensus estimates of losses per share improve by 26%

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Second quarter 2024 earnings: EPS exceeds analyst expectations

Immunocore Holdings plc to Report Q2, 2024 Results on Aug 08, 2024

Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?

New major risk - Revenue and earnings growth

Immunocore Holdings plc Announces Randomization of First Patient in the Global, Registrational Phase 3 Clinical Trial Testing Brenetafusp for the Treatment of First-Line Advanced or Metastatic Cutaneous Melanoma

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Now 20% undervalued after recent price drop

Immunocore Holdings plc Presents KIMMTRAK Clinical Data Demonstrating That Patients with Stable Disease and Confirms Tumor Reduction Have Similar Clinical Outcomes to Patients with Partial Response

Immunocore Holdings plc Appoints Ranjeev Krishana to Serve as A Class I Director

Immunocore Holdings plc Converts Phase 2/3 TEBE-AM Clinical Trial into Registrational Phase 3 Trial Evaluating KIMMTRAK for Previously Treated Advanced Cutaneous Melanoma

Now 20% undervalued after recent price drop

Consensus EPS estimates fall by 26%, revenue upgraded

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2024 earnings released: US$0.49 loss per share (vs US$0.43 loss in 1Q 2023)

Insufficient new directors

Immunocore Holdings plc, Annual General Meeting, May 23, 2024

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Board Member notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunocore Holdings plc to Report Q4, 2023 Results on Feb 28, 2024

Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline

CEO & Director notifies of intention to sell stock

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Head of Research & Development notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus EPS estimates upgraded to UK£0.80 loss, revenue downgraded

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Head of Research & Development notifies of intention to sell stock

New major risk - Revenue and earnings growth

Head of Research & Development notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Immunocore Holdings plc to Report Q2, 2023 Results on Aug 10, 2023

CEO & Director notifies of intention to sell stock

Head of Research & Development notifies of intention to sell stock

Consensus EPS estimates fall by 14%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

No longer forecast to breakeven

Consensus EPS estimates fall by 153%, revenue upgraded

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus estimates of losses per share improve by 10%

Immunocore Holdings plc Provides Revenue Guidance for the Fourth Quarter and Twelve Months Ended December 31, 2022

Immunocore Holdings plc Announces the Addition of Three New ImmTAC Product Candidates

Forecast to breakeven in 2025

Consensus forecasts updated

Immunocore Holdings plc Presents Ovarian Cancer Expansion Data for ImmTAC® candidate IMC-C103C targeting MAGE-A4

An unknown buyer acquired a 5% stake in Immunocore Holdings plc (NasdaqGS:IMCR) from Malin Corporation plc (ISE:MLC) for approximately €150 million.

Consensus forecasts updated

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Consensus revenue estimates increase by 27%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors